Variant Misclassification Is the Hidden Risk in Clinical Genomics

Next generation sequencing has become a cornerstone of modern clinical medicine. From hereditary cancer panels to rare disease diagnosis and tumor profiling, NGS is now embedded in clinical workflows across hospitals and reference labs worldwide. The technology has matured rapidly, costs have dropped dramatically, and sequencing turnaround times have shrunk from weeks to days.

But as sequencing has scaled, a quieter problem has grown alongside it — one that rarely makes headlines but carries significant consequences for patients, clinicians, and health systems alike: variant misclassification.

The Scale of the Problem

When a clinical lab sequences a patient’s genome, it doesn’t produce a simple positive or negative result. It produces a list of variants — positions in the genome that differ from a reference sequence — each of which must be evaluated and classified. The standard classification framework, developed by the American College of Medical Genetics and Genomics (ACMG), places variants into five categories: pathogenic, likely pathogenic, variant of uncertain significance (VUS), likely benign, and benign.

Those classifications drive real clinical decisions. A pathogenic finding in a BRCA gene may lead to prophylactic surgery. A likely pathogenic variant in a cardiac gene may trigger a cascade of family testing. A benign classification may rule out a genetic cause entirely. Getting these classifications wrong — in either direction — has direct consequences for patient care.

Research tracking variant reclassification rates across clinical laboratories has found that between 10 and 30 percent of variants are reclassified within three to five years of their initial classification. Some variants previously reported as pathogenic are later found to be benign. Others that were classified as uncertain are upgraded to pathogenic as new evidence emerges. Each reclassification event creates an obligation — ethical, clinical, and in some cases legal — to recontact the affected patients and update their care plans.

For labs processing hundreds or thousands of cases, that represents a significant and ongoing operational burden. And for patients, it means that a result they may have acted on could be materially different today than when it was reported.

Why Misclassification Happens

Variant misclassification is rarely the result of negligence. It is most often the result of infrastructure — specifically, the gap between what clinical genomics demands and what most lab workflows are actually built to deliver.

Classification is not a simple lookup. It requires integrating multiple layers of evidence simultaneously: population frequency data from databases like gnomAD, clinical significance data from ClinVar, functional evidence from published research, inheritance patterns from family history, and computational predictions about how a variant affects protein function. Each of these evidence sources must be evaluated against specific ACMG criteria, weighted appropriately, and documented in a way that supports clinical accountability.

Labs that rely on manual workflows — querying databases one at a time, recording decisions in spreadsheets, applying classification criteria inconsistently across analysts — are operating at a structural disadvantage. The complexity of the task, combined with the volume of variants a modern NGS run produces, makes manual interpretation both slow and error-prone at scale.

The problem compounds as testing volume grows. A workflow that is manageable at ten cases per month becomes a bottleneck at fifty and a liability at two hundred. Yet many labs have invested heavily in sequencing hardware while underinvesting in the interpretation infrastructure that sits downstream of it.

The Two Areas of Greatest Risk

The interpretation gap is particularly acute in two clinical contexts.

The first is targeted gene panel testing for inherited conditions — hereditary cancer risk, cardiac disease, pharmacogenomics, and other areas where clinical panel analysis must meet strict regulatory standards. These tests are often ordered with specific treatment implications in mind, meaning that false positives and false negatives carry immediate clinical weight. A lab that cannot consistently apply ACMG/AMP classification criteria across analysts and cases is a lab that cannot reliably meet the standard of care.

The second is whole genome sequencing, where the sheer volume and complexity of data makes manual interpretation impractical at production scale. Whole genome runs produce upward of 4 to 5 million variant calls per sample, requiring sophisticated filtering, annotation, and prioritization before any human review begins. Labs without purpose-built genome analysis software to handle this complexity are forced to rely on workarounds that don’t scale and don’t produce consistent results.

What Closing the Gap Requires

Addressing the variant misclassification problem requires rethinking the interpretation layer — not just the sequencing layer — as a clinical quality priority.

That starts with structured classification workflows. ACMG and AMP guidelines provide a framework, but applying them consistently requires software that enforces criterion-by-criterion documentation, flags incomplete evidence, and produces an audit trail that supports regulatory compliance. Classification decisions made informally, without documentation, are decisions that cannot be defended during a CAP inspection or a legal challenge.

It also requires access to current annotation data. Variant classification decisions are only as good as the evidence underlying them, and that evidence is constantly evolving. Labs operating on static database snapshots — updated once or twice a year at best — are routinely classifying variants based on information that has been superseded. Monthly-updated curated databases are the minimum standard for clinical production environments.

And it requires systematic reclassification tracking. When a variant’s classification changes, labs need a mechanism to identify every patient whose report was based on that variant and initiate a recontact process. Without structured classification records, that process is manual, time-consuming, and inconsistently executed. The right approach to genome interpretation treats reclassification not as an edge case but as a routine part of laboratory operations.

The Broader Stakes

The misclassification problem is not going to resolve itself as sequencing scales further. If anything, it will intensify. More tests, more variants, more complexity — without a corresponding investment in interpretation infrastructure, the error rate embedded in clinical genomics reporting will grow alongside the volume.

Health systems, laboratory directors, and health IT leaders who treat genomic testing as a sequencing problem have largely solved it. The next priority is treating interpretation as the clinical quality challenge it actually is — and building the infrastructure to match.

The sequencing revolution delivered on its promise. The interpretation revolution is what precision medicine needs next.